Biomarkers, Imaging Ready for Prime Time in AD Diagnosis

Post date: 2010/7/18 下午 02:26:43

July 14, 2010 (Honolulu, Hawaii) — Draft reports from 3 workgroups presented here at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 will form the basis for new diagnostic criteria for mild cognitive impairment (MCI) and Alzheimer's disease (AD) — the first update of the current criteria in 25 years.

The NIA/Alzheimer's Association working groups were organized around the three stages of Alzheimer's disease that are commonly thought to exist today – pre-clinical Alzheimer's, mild cognitive impairment (MCI) due to Alzheimer's, and Alzheimer's dementia.

  • Pre-clinical – The group is laying out a research agenda to identify methods of assessment that may help predict risk for developing the disease. Biomarkers and other clinical assessment tools to identify early cognitive decline are being investigated to establish the presence of Alzheimer's brain changes in people with no overt symptoms and to identify those who may eventually develop the disease.
  • Mild cognitive impairment – The group is refining the MCI criteria, which will help to indicate cognitive change before dementia and better differentiate MCI from Alzheimer's. Research is underway to better understand the cognitive changes taking place, how they may relate to biomarkers, and which of these methods best indicate the likelihood of imminent progression to Alzheimer's dementia.
  • Alzheimer's dementia – The group is revising the existing criteria for diagnosing Alzheimer's to include possible biomarkers and other assessments that may aid in diagnosis.